Downside for me is the following comment from Esra regarding AOD:
"I suppose when we sat down we thought, well, we can go out and partner this, but at the same time, we can leverage on the fantastic science that we've developed over the years and actually go out there and market a product.."
To me, this means there will be no deal with a big player - we are going to do it all ourselves. I would much rather we link up with a company established in this market who has the know-how, resources, and profile to pull it off.
Phosphagenics profile is virtually zilch. All we have is a small range of skin care products in Elixia, that are sold in about 1.5% of Australian pharmacies, no department stores, and no beauty salons.
I'm very dubious that this approach will give us the best return.
Regards.
POH Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)